Individual Patient Compassionate Use of Crenolanib

Arog Pharmaceuticals

Status

Conditions: FLT3/TKD Mutation; FLT3-ITD Mutation; PDGFRA Gene Amplification; PDGFR-Alpha D842V

Treatments: Drug: Crenolanib besylate

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT03620318

ARO-EAP

Details and patient eligibility

About

Compassionate use of crenolanib for patients with serious life-threatening illness that have exhausted all available therapies used to treat the disease, with no other viable therapy options, who is not eligible for clinical trials. This program is designed to evaluate the requests on a patient by patient basis.

Patients must have documented evidence of a point mutation in position 842 in platelet derived growth factor receptor alpha (PDGFRA-D842V) or amplification of PDGFRA or internal tandem duplication within the FMS-like tyrosine kinase 3 (FLT3-ITD) or point mutations within the tyrosine kinase domain (TKD) of FLT3 (FLT3-TKD)

Full description

This program is being offered on a patient by patient basis while phase 3 studies with crenolanib are ongoing.

Institutional Review Board-/Independent Ethics Committee approval must be granted before, The experimental intervention will be administered over 28-day cycles. Compassionate use of crenolanib will be limited such that it does not interfere with the supply need for phase 3 studies.

There must be adequate understanding of the indication for the requested use.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subject must have a serious life threatening cancer with FLT3/PDGFRa mutation or PDGFRa amplification who has exhausted all other treatment options
• Subject and their partner (if adults) must use 2 forms of contraception during study and for 3 months following last dose of study drug

Exclusion criteria

• Subject is eligible for enrollment in an ongoing clinical trial
• Subject has any condition which, in the investigator's opinion makes the subject unsuitable for participation